JW Holdings Corp is a Korea-based company principally engaged in the production and sale of pharmaceuticals. The Company is principally engaged in the production and sale of pharmaceuticals such as antibiotics, antifungal agents, blood and body fluids substitutes, hyperlipidemia drugs, electrolyte additives, angina pills and digestive medicines. The Company is also engaged in the manufacture and sale of diagnostic equipment for hematology, immunology and others. In addition, the Company is engaged in the holding businesses.

Employees

114

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-10-21	₩4,025.00	0.00%	35,311
26-10-20	₩4,025.00	-0.62%	66,020
26-10-19	₩4,050.00	+1.38%	30,274
26-10-16	₩3,995.00	+1.52%	65,408
26-10-15	₩3,935.00	-2.72%	108,160

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 2026-10-21			5-day change	1st Jan Change
4,025.00 ^KRW	0.00%		-0.49%	+12.12%

08-14	JW Holdings Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-15	JW Holdings Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	278B 210M 187M 173M 157M 295M 19.79B 299M 2.07B 814M 10.4B 787M 770M 33.15B	P/E 2024	3.45x	P/E 2025	4.27x
Enterprise Value	549B 413M 368M 341M 308M 581M 38.99B 588M 4.09B 1.6B 20.49B 1.55B 1.52B 65.31B	EV / Sales 2024	0.65x	EV / Sales 2025	0.53x
Free-Float	39.41%	Yield 2024	5.13%	Yield 2025	-

08-14	JW Holdings Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-15	JW Holdings Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-13	JW Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-04	JW Holdings Corporation announces Annual dividend, payable on April 24, 2026	CI
11-14	JW Holdings Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-03	Jw Holdings Q3 operating profit 5 billion won, up 38.4% from year earlier	RE
25-08-14	JW Holdings Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-07-31	Jw Holdings Q2 operating profit 3.4 billion won, down 82% from year earlier	RE
25-07-03	Sound Smithy Co Ltd announced that it has received KRW 200 million in funding from JW Holdings Corporation	CI
25-06-25	Sound Smithy Co Ltd announced that it expects to receive KRW 200 million in funding from JW Holdings Corporation	CI
25-06-25	Tranche Update on JW Holdings Corporation's Equity Buyback Plan announced on March 24, 2025.	CI
25-06-25	Tranche Update on JW Holdings Corporation's Equity Buyback Plan announced on March 24, 2025.	CI
25-06-23	JW Holdings Corporation's Equity Buyback announced on March 24, 2025 has expired with 714,439 shares, representing 1.02% for KRW 2,500 million.	CI

23-10-04	Les valeurs à suivre aujourd'hui à la Bourse de Paris - Mercredi 4 octobre 2023
23-10-04	Kering : Seán McGirr nommé Directeur de la Création d'Alexander McQueen
23-10-03	Kering : nouveau directeur création chez Alexander McQueen
23-10-03	Kering nomme Seán McGirr directeur de la création chez Alexander McQueen
23-08-18	El Kospi de Corea cae un 0,6%, su mayor racha de pérdidas desde junio de 2022 -- Market Talk

JW Holdings Corporation Stock

Stocks

A096760

KR7096760004

Pharmaceuticals

Valuation: JW Holdings Corporation

Chart: JW Holdings Corporation

Latest news: JW Holdings Corporation

News in other languages: JW Holdings Corporation

Quotes and Performance

Price Extremes

Managers and Directors: JW Holdings Corporation

Latest insider transactions

Generic Pharmaceuticals

Financials

Company Profile

Quotes

1 week	-0.49%
Current month	-5.41%
1 month	-7.68%
3 months	+5.50%
6 months	-4.28%
Current year	+12.12%

1 week	3,855	4,095
1 month	3,855	4,395
Current year	3,300	4,720
1 year	3,195	4,720
3 years	2,650	4,720
5 years	2,536.65	4,720
10 years	2,536.65	11,846.96

Manager	Title	Age	Since
Seong-Nam Cha CEO	Chief Executive Officer	69	2024-03-26
Kyung-Ha Lee CEO	Chief Executive Officer	63	-
Ji-Woo Choi DFI	Director of Finance/CFO	60	2020-03-26

Director	Title	Age	Since
Kyung-Ha Lee CHM	Chairman	63	-
Chan-Yeop Yeom BRD	Director/Board Member	64	2020-03-26
Ji-Woo Choi BRD	Director/Board Member	60	2020-03-26

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
2/7/24	Sung-Kweon Han	Free	Chief Executive Officer	215	0.0003%
2/7/24	Gui-eung Song	Free		4	0.0000%	-
2/7/24	Kyung-Ha Lee	Free	Chief Executive Officer	412,069	0.5574%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JW HOLDINGS CORPORATION	0.00%	-0.49%	+23.85%	+26.91%	210M
ELI LILLY AND COMPANY	-1.01%	+5.13%	+58.93%	+117.36%	1,133B
JOHNSON & JOHNSON	-0.61%	+1.52%	+34.34%	+68.48%	621B
ABBVIE INC.	-1.48%	+0.47%	+23.08%	+94.76%	503B
ROCHE HOLDING AG	+0.54%	+5.69%	+39.60%	+64.02%	379B
MERCK & CO., INC.	+1.07%	+1.70%	+71.06%	+45.98%	370B
NOVARTIS AG	+0.30%	+3.44%	+21.35%	+49.62%	292B
ASTRAZENECA PLC	-0.03%	+2.55%	+1.12%	+20.94%	262B
AMGEN INC.	-0.14%	+2.87%	+45.56%	+57.22%	237B
GILEAD SCIENCES, INC.	-1.88%	+0.02%	+23.77%	+97.39%	190B
Average	-0.03%	+3.12%	+34.27%	+64.27%	398.82B
Weighted average by Cap.	+0.33%	+3.73%	+40.83%	+79.37%

	2024	2025
Net sales	888B 669M 596M 552M 499M 940M 63.09B 952M 6.61B 2.6B 33.16B 2.51B 2.46B 106B	970B 730M 651M 602M 545M 1.03B 68.91B 1.04B 7.22B 2.83B 36.22B 2.74B 2.68B 115B
Net income	62.62B 47.16M 42.03M 38.91M 35.21M 66.34M 4.45B 67.13M 467M 183M 2.34B 177M 173M 7.45B	58.5B 44.06M 39.27M 36.35M 32.9M 61.98M 4.16B 62.72M 436M 171M 2.19B 165M 162M 6.96B
Net Debt	362B 272M 243M 225M 203M 383M 25.71B 388M 2.69B 1.06B 13.51B 1.02B 1B 43.06B	270B 203M 181M 168M 152M 286M 19.2B 290M 2.01B 790M 10.09B 763M 747M 32.15B